{"id":"W4401877385","doi":"10.1016/s2152-2650(24)01700-2","title":"MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Dexamethasone; Bortezomib; Internal medicine; Oncology; Refractory (planetary science); Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00316664,0.001559942,0.003289444,0.0004359064,0.0005345537,0.001276658,0.00127005,0.001356634,0.006056098],"category_scores_gemma":[0.002279649,0.0006374433,0.004412871,0.0005138254,0.0008329965,0.00107031,0.0008239386,0.003793519,0.0008076202],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001355301,"about_ca_system_score_gemma":0.00121013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001209817,"about_ca_topic_score_gemma":0.003232572,"domain_scores_codex":[0.9982157,0.001164606,0.00009805096,0.0001974291,0.0001360542,0.0001882829],"domain_scores_gemma":[0.998519,0.0004406455,0.0004623145,0.0001173069,0.00008339659,0.0003772333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9731551,0.002183798,0.004551782,0.0004158831,0.004329252,0.00003115731,0.00003134854,0.0007065729,0.001310018,0.0001268655,0.001807212,0.01135097],"study_design_scores_gemma":[0.9295906,0.04549865,0.01743784,0.00007888571,0.003993527,0.00007652307,0.00004900046,0.0006734695,0.0005453867,0.0003582675,0.001660299,0.00003750112],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802666,0.007533301,0.0005598009,0.001118293,0.0004189434,0.001444181,0.00563837,0.00009221053,0.002928351],"genre_scores_gemma":[0.980643,0.002257581,0.001567783,0.001764769,0.0004676253,0.002511427,0.008232157,0.00004169493,0.002513849],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006056098,"threshold_uncertainty_score":0.02025968,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03474061764353763,"score_gpt":0.33254429824586,"score_spread":0.2978036806023224,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}